Metabolomics of bronchopulmonary dysplasia.
BPD
Biomarker
Lung
Metabolomics
Microbiomics
Preterm infant
Journal
Clinica chimica acta; international journal of clinical chemistry
ISSN: 1873-3492
Titre abrégé: Clin Chim Acta
Pays: Netherlands
ID NLM: 1302422
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
received:
07
08
2019
revised:
20
09
2019
accepted:
20
09
2019
pubmed:
7
11
2019
medline:
3
6
2020
entrez:
6
11
2019
Statut:
ppublish
Résumé
The pathogenesis of Bronchopulmonary dysplasia (BPD) remains poorly understood. It is a multifactorial disease having a genetic-environmental basis. Although attempts have been made to identify a biomarker, none have been validated for clinical use to date. Metabolomics is a promising field of the "omics technologies" that could allow for better understanding of the pathogenesis and underlying mechanisms of BPD as well as facilitate detection of biomarkers. Identification of these biomarkers would improve diagnosis, identify patients in early disease stages and potentially target intervention. This review focuses on the evidence arising from metabolomics and its interaction with microbiomics and pharmacology with respect to pathogenesis and treatment options for this multifactorial complex disease.
Identifiants
pubmed: 31689411
pii: S0009-8981(19)32057-1
doi: 10.1016/j.cca.2019.09.025
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
109-114Informations de copyright
Copyright © 2019 Elsevier B.V. All rights reserved.